ABSTRACT
Enoxaparin [Clexane] is a low molecular weight heparin with a molecular weight of around 4500 D. It is a blood thinner used to treat pulmonary embolism, Deep vein thrombosis, unstable angina, non-ST elevated myocardial infarction and ST- segment elevation myocardial infarction. This project is designed to evaluate the most widely used Low molecular weight heparin [LMWH], enoxaparin in patients with Acute Coronary Syndrome [ACS] based on prescriptions evaluation. Prescriptions were collected from different health institutes and were evaluated on the basis of Market Share, MIP data-competitors, MIP data-indication, and on MIP data-specialty. The study included both male and female patients of age ranging between 50-70 years. The results reflect the prescription patterns of enoxaparin [Clexane] by evaluating 73 prescriptions from major cardiovascular hospitals in Pakistan between February 2008 and October 2008. The prescription pattern showed that physicians in Pakistan have a tendency of prescribing enoxaparin with other drugs. The results also showed that patients were prescribed multiple anti-coagulants concomitantly, including enoxaparin and aspirin. Overall, the analysis of anti-coagulants has indicated that enoxaparin is the drug of choice for the treatment of ACS